MEK-ERK Pathway Modulation Ameliorates Disease Phenotypes in a Mouse Model of Noonan Syndrome Associated With the Raf1L613V Mutation

Journal of Clinical Investigation- United States

doi 10.1172/jci44929

Full Text

Abstract

Available in

Categories

Date

March 1, 2011

Authors

Nirusha K. Thavarajah

Benjamin G. Neel

Toshiyuki Araki

Publisher

American Society for Clinical Investigation

Related search

Modulation of the Akt/Ras/Raf/Mek/Erk Pathway by A3 Adenosine Receptor

Purinergic Signalling

Molecular Neuroscience

Molecular Biology

English

A First Case Report of Subependymoma in PTPN11 Mutation-Associated Noonan Syndrome

Case Reports in Neurological Medicine

English

A YWHAZ Variant Associated With Cardiofaciocutaneous Syndrome Activates the RAF-ERK Pathway

Frontiers in Physiology

English

Noonan Syndrome: Comparing Mutation-Positive With Mutation-Negative Dutch Patients

Molecular Syndromology

English

Cancer Risk in Patients With Noonan Syndrome Carrying a PTPN11 Mutation

European Journal of Human Genetics

English

Modulation of mtDNA Copy Number Ameliorates the Pathological Consequences of a Heteroplasmic mtDNA Mutation in the Mouse

Science advances

Multidisciplinary

English

Genotype and Phenotype in Patients With Noonan Syndrome and a RIT1 Mutation

Genetics in Medicine

English

Leukemia Inhibitory Factor (LIF) Withdrawal Activates mTOR Signaling Pathway in Mouse Embryonic Stem Cells Through the MEK/ERK/TSC2 Pathway

Cell Death and Disease

Molecular Neuroscience

Cancer Research

English

Loss of the BMP Antagonist USAG-1 Ameliorates Disease in a Mouse Model of the Progressive Hereditary Kidney Disease Alport Syndrome

Journal of Clinical Investigation

English